Pulmonx マネジメント
マネジメント 基準チェック /24
Pulmonxの CEO はGlen Frenchで、 Oct2025年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 3.54Mで、 3.3%給与と96.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.3%を直接所有しており、その価値は$ 1.50M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と6.3年です。
主要情報
Glen French
最高経営責任者
US$3.5m
報酬総額
| CEO給与比率 | 3.28% |
| CEO在任期間 | less than a year |
| CEOの所有権 | 2.3% |
| 経営陣の平均在職期間 | 3.2yrs |
| 取締役会の平均在任期間 | 6.3yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 02
LUNG: Execution Improvements And Fundamentals Focus Will Support Future Turnaround Confidence
Analysts have trimmed their price target on Pulmonx to $5 from $6, reflecting Q4 results that were largely in line and management's efforts to address internal issues while refocusing on the fundamentals that previously supported the business. Analyst Commentary Bullish analysts are emphasizing that the trimmed US$5 price target still reflects confidence that Pulmonx can execute on its plan to resolve internal issues and refocus on the fundamentals that previously supported the business.
ナラティブの更新 • Apr 18
LUNG: Fundamental Reset And Cleaner Execution Will Support Future Upside
Analysts have trimmed their Pulmonx price target to $5 from $6, citing largely in line Q4 results, management's explanation of last year's internal issues, and the company's renewed focus on the fundamentals that supported its earlier success. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$5 price target as reflecting a more grounded expectation for execution, with Q4 results described as largely in line rather than a negative surprise.ナラティブの更新 • Apr 04
LUNG: Cleaner Execution And Fundamentals Refocus Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to $5 from $6, pointing to Q4 results that were largely in line and to management's efforts to fix last year's internal issues while refocusing on the core fundamentals of the business. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q4 results being largely in line supports the current valuation reset, even with the lower US$5 price target.ナラティブの更新 • Mar 21
LUNG: Cleaner Execution And 2026 Revenue Guidance Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to about $5.17 from $5.75, reflecting updated views on revenue growth, profit margin expectations, and the impact of recent operational issues highlighted in Q4 commentary. Analyst Commentary Recent research suggests that the lower price target reflects a reset of expectations around execution while still acknowledging the core business case.ナラティブの更新 • Mar 06
LUNG: Operational Reset And Fundamentals Focus Will Support Turnaround Confidence
Analysts have lowered their price target on Pulmonx by $1 to $5, citing Q4 results that were broadly in line with expectations, while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more cautious, but still constructive, stance on Pulmonx.ナラティブの更新 • Feb 20
LUNG: Refined Risk And Margin Outlook Will Support Turnaround Confidence
Analysts have adjusted their Pulmonx price targets to reflect updated assumptions on discount rate, revenue growth, profit margin, and future P/E, keeping fair value around $13.49 while fine tuning the risk and earnings profile in their models. Valuation Changes Fair Value: Model fair value is unchanged at $13.49, indicating updated inputs did not shift the overall valuation level.分析記事 • Feb 11
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...ナラティブの更新 • Feb 06
LUNG: Firm Guidance And Margins Will Support Future Upside Potential
Analysts have kept their Pulmonx fair value estimate steady at US$5.75, with a slightly higher discount rate and P/E assumptions guiding the updated price target rationale. What's in the News Pulmonx issued new earnings guidance for full year 2025, setting an expected total revenue range of US$89 million to US$90 million.ナラティブの更新 • Jan 23
LUNG: Prior Leadership Return Will Drive Confidence In Turnaround Story
Narrative Update on Pulmonx Analysts have cut their price target on Pulmonx from $8 to $4, pointing to revised fair value assumptions and a lower future P/E multiple. At the same time, they highlight prior leadership returning and continued confidence in the Zephyr valves concept and the broader market opportunity.分析記事 • Jan 10
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...ナラティブの更新 • Jan 08
LUNG: Returning Leadership And Clinical Traction Will Support Future Upside Potential
Analysts have trimmed their price target on Pulmonx to US$4.00 from US$8.00, citing a reassessment of valuation, the return of prior leadership, and ongoing confidence in the clinical proof of concept for Zephyr valves and the broader market opportunity. Analyst Commentary Recent research commentary focuses on how the lower price target, leadership changes, and clinical track record of Zephyr valves fit together for investors weighing risk and potential reward.ナラティブの更新 • Dec 24
LUNG: Returning Leadership Will Drive Confidence Amid Near-Term Execution Uncertainty
Analysts have reduced their price target on Pulmonx to approximately $4.00 from $8.00, citing near term uncertainty around leadership changes but continued confidence in the long term opportunity, supported by Zephyr valve clinical validation and the broader product pipeline. Analyst Commentary Bullish Takeaways Bullish analysts highlight that even after the reduced price target, the implied upside still represents roughly a potential doubling from recent after hours trading levels, which underscores a favorable risk reward profile.ナラティブの更新 • Dec 10
LUNG: Returning Leadership Will Drive Confidence And Unlock Significant Upside Ahead
Analysts have reduced their price target on Pulmonx to about $4 from roughly $8, citing a lower discount rate along with confidence in returning leadership, robust clinical validation of Zephyr valves, and a solid market and pipeline opportunity that they still see as supporting substantial upside from current levels. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the lowered price target still implies meaningful upside from current trading levels, suggesting the market may be underestimating the company’s long term earnings potential.分析記事 • Dec 05
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has done very well over the last month, posting an excellent gain...ナラティブの更新 • Nov 26
LUNG: Returning Leadership Will Restore Confidence And Unlock Upside In Coming Year
Analysts have revised their price target for Pulmonx downward from $8 to $4 per share. They cite ongoing confidence in the company's clinical proof of concept and market opportunities, even in light of unexpected executive changes.ナラティブの更新 • Nov 12
LUNG: Leadership Transition Will Drive Renewed Execution Strength In The Coming Year
Analysts have revised Pulmonx’s price target downward from $8.00 to $4.00. They cite both leadership changes and ongoing belief in the company’s clinical achievements and long-term market potential as rationale for the adjustment.ナラティブの更新 • Oct 29
Leadership Return And Clinical Strength Will Drive Long-Term Market Opportunity
Analysts have lowered their price target for Pulmonx from $6.75 to $5.75, reflecting adjusted expectations on revenue growth and valuation. They remain optimistic, however, due to strong clinical evidence and a promising leadership transition.分析記事 • Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward
Those holding Pulmonx Corporation ( NASDAQ:LUNG ) shares would be relieved that the share price has rebounded 47% in...分析記事 • May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 40% in the last...分析記事 • Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...
新しいナラティブ • Apr 01
LungTrax And Global Expansion Will Broaden Market Access
Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.分析記事 • Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Pulmonx Corporation ( NASDAQ:LUNG ) will be pleased this week, given that the stock price is up 19% to...分析記事 • Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)
There wouldn't be many who think Pulmonx Corporation's ( NASDAQ:LUNG ) price-to-sales (or "P/S") ratio of 3.2x is worth...分析記事 • Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 26% in the last...Seeking Alpha • Jul 21
Pulmonx: Low Bar For Q2 Earnings
Summary New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses. Read the full article on Seeking Alpha分析記事 • Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • Apr 04
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Pulmonx Corporation ( NASDAQ:LUNG ) is a stock to...Seeking Alpha • Mar 26
Pulmonx: Revisiting Thesis Following Management Change
Summary Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate strategy. In my opinion, the market for endobronchial valves is much smaller than anticipated, and LUNG should sell itself to a larger conglomerate. Read the full article on Seeking Alpha分析記事 • Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$53m |
| Dec 31 2025 | US$4m | US$116k | -US$54m |
| Sep 30 2025 | n/a | n/a | -US$57m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$57m |
| Dec 31 2024 | US$717k | US$196k | -US$56m |
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$580k | -US$61m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$5m | US$569k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$5m | US$550k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$3m | US$443k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$1m | US$412k | -US$21m |
報酬と市場: Glenの 総報酬 ($USD 3.54M ) は、 US市場 ($USD 630.36K ) の同規模の企業の平均を上回っています。
報酬と収益: Glenの報酬は増加しましたが、会社は利益を上げていません。
CEO
Glen French (63 yo)
less than a year
在職期間
US$3,543,520
報酬
Mr. Glendon E. French, also known as Glen, had been an Independent Director of EDAP TMS S.A. since February 27, 2025 until February 10, 2026. He serves as Director of Pulmonx Corporation from December 2014...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.54m | 2.3% $ 1.5m | |
| CFO & COO | less than a year | US$2.95m | 0.32% $ 208.4k | |
| General Counsel & Secretary | 5.6yrs | US$1.71m | 0.21% $ 136.9k | |
| Chief Science & Technology Officer | 6.3yrs | データなし | 0.82% $ 532.4k | |
| Vice President of Marketing | no data | データなし | データなし | |
| Chief People Officer | 4.3yrs | データなし | データなし | |
| Senior VP & GM of International | no data | データなし | データなし | |
| Chief Commercial Officer | 6.3yrs | US$1.96m | 0.53% $ 344.5k | |
| Senior Vice President of Global Medical & Clinical Affairs | less than a year | データなし | データなし | |
| VP of Finance & Corporate Controller | 2.1yrs | データなし | データなし |
3.2yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: LUNGの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 11.4yrs | US$3.54m | 2.3% $ 1.5m | |
| Independent Chairperson of the Board | 16.3yrs | US$211.29k | 0.16% $ 102.6k | |
| Independent Director | 18.4yrs | US$181.29k | 0.12% $ 76.8k | |
| Independent Director | 5.7yrs | US$181.29k | 0.15% $ 96.3k | |
| Independent Director | 5.7yrs | US$168.79k | 0.086% $ 55.8k | |
| Independent Director | 6.3yrs | US$188.79k | 0.22% $ 144.6k | |
| Independent Director | 4.8yrs | US$166.29k | 0.090% $ 58.6k |
6.3yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: LUNGの 取締役会 は 経験豊富 であると考えられます ( 6.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 09:16 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Pulmonx Corporation 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |